Market Highlights
According to MRFR analysis, Bronchodilators Market Trends is expected to register a CAGR of 5.30%
during the forecast period of 2019 to 2025 and is expected to reach USD
2,484 Million by 2025.
Bronchodilators are medications
that make breathing easier by opening the airways of the lung by relaxing
bronchial muscles. They are used to treat various respiratory problems such as
asthma, COPD, and other allergic reactions that cause breathing problems.
The growth of the global Bronchodilators
Market Trends is driven by various factors such as increase in prevalence of
pulmonary disorders, increasing geriatric population and increasing mergers and
acquisitions by prominent players in the market. However, side effects
associated with bronchodilators and government regulations related to the
safety & efficacy of the bronchodilators are projected to hamper the growth
of the global Bronchodilators Market Trends.
The global Bronchodilators Market
Trends is currently dominated by several market players. The key players are
involved in product launches and strategic collaborations to strengthen their
market positions. For instance, in April 2019, Cipla Technologies
entered into agreement with Pulmatrix Inc. to co-develop a formulation for the
treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with
asthma.
Segmentation
The global Bronchodilators Market
Trends has been segmented based on drug type, disease, mode of action, and
route of administration.
The market, based on drug type,
has been divided into adrenergic drugs, anticholinergics, a phosphodiesterase
inhibitor, and combination drugs.
The adrenergic segment is likely
to be the largest during the review period as they are the most potent
bronchodilators approved for clinical use in asthma and obstructive lung
disease. The combination drugs segment is predicted to be the fastest-growing segment.
These combination drugs are used if COPD and asthma are not controlled with
monotherapy. These combinations involving two long-acting bronchodilators with
differing modes of action.
The global Bronchodilators
Market Trends has been segmented, on the basis of disease, into asthma, COPD, and
others. The asthma segment is expected to hold the majority share of the
market, owing to the rise in patients affected with asthma. The COPD segment is
expected to be the fastest-growing as bronchodilators are primary treatment for
chronic obstructive pulmonary disease (COPD) as they help to alleviate
bronchial obstruction and airflow limitation.
In terms of mode of
action, the global Bronchodilators Market Trends has been segmented into
short-acting bronchodilators and long-acting bronchodilators. Short-acting
bronchodilators are expected to be the largest segment, owing to its ability to
provide quick relief from sudden, unexpected attacks of breathlessness.
The route of administration of
the market is oral and parenteral. The oral route of administration segment is
expected to hold the largest share of the market due to the advantages such as
ease and simplicity of administration along with control of delivered dose.
Key Players
Some of the key
players in the Global Bronchodilators Market Trends are GlaxoSmithKline (UK), Novartis AG (Switzerland),
Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH
(Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva
Pharmaceutical (Israel) and Pfizer Inc. (US) among others.
Regional Analysis
The market has been divided, by
region, into the Americas, Europe, Asia-Pacific, and the Middle East &
Africa. The Americas are expected to be the largest market owing to the rising
per capita healthcare expenditure. The Bronchodilators Market Trends in the
Americas has further been branched into North America and Latin America, with
the North American market divided into the US and Canada. The European Bronchodilators
Market Trends has been categorized as Western Europe and Eastern Europe. The
Western European market has further been classified as Germany, France, the UK,
Italy, Spain, and the rest of Western Europe. The Bronchodilators Market Trends
in Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of
respiratory disorders and the increasing pool of patient population, the market
in Asia-Pacific is expected to be the fastest-growing. The Bronchodilators
Market Trends in the Middle East & Africa has been divided into the Middle
East and Africa.
No comments:
Post a Comment